Daxor Research and Development Expenses 2012-2011 | DXR

Daxor research and development expenses from 2012 to 2011. Research and development expenses can be defined as an expense arising from studies and product development processes.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Daxor Annual Research and Development Expenses
(Millions of US $)
2011 $3
Daxor Quarterly Research and Development Expenses
(Millions of US $)
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $0.057B $0.000B
Daxor Corporation is a medical device manufacturing corporation with additional biotech services.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $25.391B 11.38
Quest Diagnostics (DGX) United States $21.586B 19.23
DaVita (DVA) United States $13.348B 17.73
Elanco Animal Health (ELAN) United States $12.097B 24.71
Encompass Health (EHC) United States $9.724B 17.23
Chemed (CHE) United States $5.791B 22.16
RadNet (RDNT) United States $4.226B 116.83
LifeStance Health (LFST) United States $3.483B 149.67
Option Care Health (OPCH) United States $3.453B 14.28
Astrana Health (ASTH) United States $2.182B 26.47
Addus HomeCare (ADUS) United States $1.759B 16.62
Aveanna Healthcare Holdings (AVAH) United States $1.696B 12.77
Pennant (PNTG) United States $1.163B 32.47
U.S Physical Therapy (USPH) United States $0.964B 24.35
MEDIROM Healthcare Technologies (MRM) Japan $0.033B 0.00
Psychemedics (PMD) United States $0.000B 0.00